Shares of Medivation Inc (NASDAQ:MDVN) ended Monday session in green amid volatile trading. The shares closed up +0.03 points or 0.04% at $80.90 with 165.93 million shares getting traded. Post opening the session at $80.94, the shares hit an intraday low of $80.87 and an intraday high of $81.07 and the price vacillated in this range throughout the day. The company has a market cap of $13.39 billion and the numbers of outstanding shares have been calculated to be 165.93 million shares.
Medivation Inc (MDVN), a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (CRPC) patients. The company also develops Enzalutamide, which is in phase III clinical trials for the treatment of non-metastatic CRPC, and metastatic and non-metastatic hormone sensitive prostate cancer; and phase II clinical trials for the treatment of hepatocellular carcinoma, androgen receptor positive (AR+) triple negative breast cancer, estrogen receptor positive or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal breast cancer, and AR+ HER2 amplified breast cancer.
Shares of Array Biopharma Inc (NASDAQ:ARRY) ended Monday session in green amid volatile trading. The shares closed up +0.23 points or 6.47% at $3.70 with 145.02 million shares getting traded. Post opening the session at $3.52, the shares hit an intraday low of $3.50 and an intraday high of $3.73 and the price vacillated in this range throughout the day. The company has a market cap of $531.23 million and the numbers of outstanding shares have been calculated to be 145.02 million shares.
Array Biopharma Inc (ARRY) on Sept. 14, 2016 announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) related to BEACON CRC, a global Phase 3 trial of encorafenib and Erbitux® (cetuximab), with or without binimetinib, versus standard of care in patients with BRAF-mutant colorectal cancer (CRC) who have previously received first-or second-line systemic therapy.
“Colorectal cancer is the third most common cancer among men and women in the United States and BRAF-mutant CRC represents a high unmet medical need, as there are currently no targeted treatment options available for patients with this form of the disease,” said Scott Kopetz, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center in Houston and BEACON CRC investigator. “The SPA agreement between Array and the FDA represents a welcome next step for the CRC community and, as a physician, I look forward to exploring these novel treatment combinations.”